

### **Annex III**

#### **Conditions for lifting the suspension of the marketing authorisations**

For the suspension to be lifted, the Marketing Authorisation Holders would need to provide the National Competent Authorities with the following:

Convincing data to identify a patient population in which the benefits of meprobamate clearly outweigh its identified risks.